Pathophysiological Study of the Increase in Pancreatic Volume in Type 2 Diabetes Treatments.

NCT02244164 · Terminated

Last updated 2026-05-28

This study is testing how treatments for type 2 diabetes, specifically incretinomimetics, affect the size of the pancreas in people with type 2 diabetes.

Status Terminated Stopped early and will not restart.

Phase Not applicable Not a phased drug trial (e.g. a device or behavioral study).

Type Interventional (clinical trial)

Design Non-randomized, open-label (no blinding) prevention study

Participants 5 people

Who can join Ages 18–75 · all sexes

Timeline Started 2014-10 · est. completion 2023-02

Where 1 site · Belgium

What this study is testing ClinicalTrials.gov NCT02244164 ↗

Description as written by the study sponsor.

Incretinomimetics and inhibitors of dipeptidyl peptidase-4 (DPP-4) are new treatments for diabetes. Previous retrospective studies have shown that these treatments induced an increase in pancreatic mass with potentially a risk for pancreatitis and development of precancerous lesions. The aim of our study is to provide a better understanding of the pathophysiological mechanisms of increased volume and / or pancreatic exocrine secretion when exposed to certain treatment of type 2 diabetes.

Treatments tested

Incretinomimetics also known as - exenatide (Byetta®), - liraglutide (Victoza®), - lixisenatide (Lyxumia®), - exenatide extended-release (Bydureon®). Drug
DPP-4 inhibitors also known as - sitagliptine (Januvia®), - vildagliptine (Galvus®), - saxagliptine (Onglyza®), - linagliptine (Trajenta®). Drug

Main thing measured	Volumetric measurement of the pancreas
Sponsor	Erasme University Hospital
Conditions studied	Type 2 Diabetes, Incretinomimetics, Pancreas
GLP-1 drugs	—

Full protocol, eligibility, and contacts on ClinicalTrials.gov NCT02244164 ↗